Cellular Technologies

Modeling the contribution of common variants to schizophrenia risk.

Monday, February 5
3:00 PM - 3:30 PM
Location: 6D

Schizophrenia (SZ) is a debilitating psychiatric disorder for which the complex genetic mechanisms underlying the disease state remain unclear. Whereas highly penetrant variants have proven well-suited to human induced pluripotent stem cell (hiPSC)-based models, the power of hiPSC-based studies to resolve the much smaller effects of common variants within the size of cohorts that can be realistically assembled remains uncertain. We identified microRNA-9 as having significantly downregulated levels and activity in a subset of SZ hiPSC-derived neural progenitor cells NPCs, a finding that was corroborated by a larger replication cohort and further validated by an independent gene-set enrichment analysis of the largest SZ genome-wide association study (GWAS) to date. Overall, this demonstrated a remarkable convergence of independent hiPSC- and genetics-based discovery approaches. In developing this larger case/control SZ hiPSC cohort of hiPSC-derived NPCs and neurons, we identified a variety of sources of variation, but by reducing the stochastic effects of the differentiation process, we observed a significant concordance with two large post mortem datasets. We predict a growing convergence between hiPSC and post mortem studies as both approaches expand to larger cohort sizes. Meanwhile, we have been integrating CRISPR-mediated gene editing, activation and repression technologies with our hiPSC-based neural platform, in order to develop a scalable system for testing the effect of a manipulating the growing number of SZ-associated variants and genes in NPCs, neurons and astrocytes. Altogether, our objective is to understand the cell-type specific contributions of SZ risk variants to disease predisposition.

Kristen Brennand

Associate Professor

Kristen Brennand, PhD is an Associate Professor of Genetics and Genomics, Neuroscience and Psychiatry at the Icahn School of Medicine at Mount Sinai, in New York, New York. She trained in developmental and stem cell biology at Harvard University and in neurobiology during postdoctoral at the Salk Institute for Biological Studies. By combining expertise in stem cell biology and neurobiology, she has pioneered a new approach by which to study psychiatric disease. Dr. Brennand’s work is funded by the National Institutes of Health, the New York Stem Cell Foundation, the Brain Research Foundation and the Brain and Behavior Research Foundation.


Send Email for Kristen Brennand


Modeling the contribution of common variants to schizophrenia risk.

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Modeling the contribution of common variants to schizophrenia risk.